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The aim of the study was to determine the cardiovascular dis)
eases and comorbidity in patients with chronic heart failure
and preserved ejection fraction depending on age. It was
found that all patients with chronic heart failure with pre)
served ejection fraction have comorbid pathology. Revealed
heterogenity age changes in the comorbidity: prevalence of
functional renal changes, chronic obstructive pulmonary dis)
ease, anemia increases with age. Moreover in all age groups,
almost half of patients had obesity and a quarter of patients –
diabetes mellitus type 2.
Key words: chronic heart failure, preserved ejection fraction,
comorbidity, age.
Despite advances in modern medicine, heart failure is still themost common complication of many cardiovascular diseases
and a major factor in mortality in the older age group [1, 3, 4, 6, 16,
19]. The growth rate of the chronic heart failure (CHF) occupies
the first place among all cardiovascular diseases and the frequency
of CHF increases with age [5, 9]. Recent studies of heart failure
indicate a change in the patients composition depending on the left
ventricular systolic function – increase in patients with heart fail1
ure and preserved left ventricle ejection fraction (LVEF) [5, 11,
12]. Increase of life expectancy in the world and population ageing,
accumulation of cardiac and comorbid disease (anemia, endocrine
diseases, diseases of the respiratory system, renal disease),
increased mortality in the female population may be associated
with an increase of CHF in particular with preserved ejection frac1
tion [2, 9]. Modern methods of CHF treatments don’t provide any
decrease of mortality of patients with preserved ejection fraction,
regardless of age and etiology of the disease [1]. Possibly patient
survival depends not only on the etiology, but also on hemody1
namic variant of CHF and comorbidity. It is possible that the role
of the above mentioned mechanisms changes with age. In addition,
there is no concrete protocol for diagnostics and treatment of heart
failure with preserved ejection fraction [5, 15]. All of the above
makes it necessary to look for possible factors in the development
and progression of heart failure with preserved ejection fraction.
Literature review
Chronic heart failure (CHF) is a potentially fatal complica1
tion of any cardiovascular disease [1, 9]. Number of patients with
chronic heart failure in the general population increases, which
reduces the quality of life and rises the risk of adverse clinical
results [4]. Unfortunately, modern treatment of heart failure is
not yet able to influence the reduction of mortality of these
patients to the population level [1, 4, 5, 9, 12].
Despite the presence of clinical signs of dysfunction,
almost half of all patients have CHF with preserved LVEF
[14]. More often CHF with preserved ejection fraction is pres1
ent in the female population, in elderly patients with hyper1
tension, anemia, obesity, chronic kidney disease, diabetes mel1
litus, chronic obstructive pulmonary disease [4]. It is proved
that the risk of death for patients with reduced LVEF is sig1
nificantly higher compared to those with preserved LVEF,
despite the fact that the progress of CHF has a poor prognosis
[2]. It is also well known that among patients with CHF with
reduced LVEF, patients with LVEF >35–40% have better
prognosis for survival, as well as the patients who have LVEF
>45% after treatment [8].
According to modern concepts, comorbid conditions seen as
a direct cause of heart failure (hypertension, diabetes, obesity) [
19]. Systemic inflammatory response reduces bioavailability of
endogenous vasodilators and increases the activity of oxidative
stress, which contributes to endothelial dysfunction and arterial
endocardium. This artery endothelial dysfunction and endo1
cardium consider essential for the development microvascular
dysfunction of cardiomyocytes [1].
The approaches to the diagnosis and treatment of CHF
with preserve EF are not developed and not approved [5, 10].
Resolving of this issue is very important because the point of
this question depends on the choice of tactics and strategy of
the CHF treatment. It is well1known that the development of
cardiovascular disease, including CHF, has «classic» risk fac1
tors such as age, male gender, smoking, heredity, hypertension,
obesity, diabetes and they play an important role [4]. However,
about half the cardiovascular disease occur with none of modi1
fied most of these risk factors [16]. In connection with this
important study factors determining peculiarities of heart fail1
ure in different age groups, the development of decompensa1
tion, the risk of adverse outcome in the end survival prognosis
of patients in each case.
We can assume that survival of patients depends not only on
the etiology, but also on hemodynamic option of CHF and comor1
bidity. With increasing life expectancy, comorbid diseases
increase, and that possibly is a prevailing reason of the progression
of heart failure [1]. The age certainly is significant in comorbidity,
but how the way it affects key indicators is still not defined.
The aim was to determine the cardiovascular diseases and
comorbidity in patients with chronic heart failure and preserved
ejection fraction depending on age.
MATERIALS AND METHODS
A retrospective analysis of clinical records of 198 patients
with CHF with preserved ejection fraction (EF more than 45%,
average (M±m) – (63,8±6,3%) was conducted. All patients were
hospitalized in 2015 and were older than 40 years (average age
(M±m) of 51,7±9,4). 53,5% were males (n=106), 46,5% – females
(n=92). With regard to the research and objectives, all patients
were divided into three groups according to age: the first group –
patients aged 40 to 59 years (n=74), the second group – patients
aged 60 to 75 years (n=73), the third group 1 patients older than
75 years (n=51). The research design is shown in Fig. 2.1.
The inclusion criteria for patients in this research were: ver1
ified CHF; LVEF 45%.
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Exclusion criteria: acute heart failure; CHF with ejection
fraction less than 45%; myocardial infarction in anamnesis up to
6 months; stroke in the anamnesis up to 6 months; surgical heart
intervention in history; acute renal injury. 
CHF was diagnosed in case of presence of objective and
subjective features inherent to this clinical syndrome, collect1
ed anamnesis, physical examination, laboratory and instru1
mental analysis (urinalysis, blood test, ECG, X1ray of the
chest cavity, doppler1echocardiography, creatinine measure1
ment, uric acid test). The diagnosis of CHF was set in the
presence of clinical criteria, using the CHF Ukrainian
Scientific Society of Cardiology classification, which was
adopted in 2002 [5, 9]. Well1known clinical criteria of New
York Heart Association (NYHA, 1964) were used to deter1
mine the functional class of patients [10].
The presence of hypertension (AH) and its stage were veri1
fied using classifications adopted in Ukraine and recommended
for use in practice according to the Decree № 384 from
24.05.2012. To achieve the chosen aim, parameters were studied
with the use of complying research protocol.
The method of body mass index evaluation. BMI was calcu1
lated using the standart formula [3].
Glomerular filtration rate (GFR) was calculated for the clin1
ical evaluation of kidney function. The wide1spread formula,
derived during international multi1center study «Modification
of Diet in Renal Disease Study (MDRD)» was used [13].
Concomitant kidney disease, thyroid cancer, obesity, dia1
betes, arrhythmias and conduction of the heart were determined
in all patients.
Patients underwent ECG using an electrocardiograph in 121
lead: 6 – from the extremities (I, II, III, aVR, aVL, aVF), and 6
chest lead (V11V6). ECG changes that indicate myocardial
infarction were found among 52 patients (26,2%).
Indicators of intracardiac hemodynamics were assessed by
echocardiographic examination on the unit «VIVID 3», GE
Medical Systems in the left lateral position of patients.
Measurements were carried out according to the recommenda1
tions of the American Society of echocardiography [5]. 
The methods of statistic analysis. Statistic processing of
materials research conducted using the methods of biostatistics
[6] implemented in the software package STATISTICA v.6.1
(Statsoft Inc., USA). Initial processing of the data was carried
out by descriptive statistics with presentation of results for
quantitative traits as: number of observations (n), the arithmetic
mean (M), standard error of the mean value (m), median (Me);
for qualitative attributes – in the form of ratios (intensive,
extensive, indicators of visibility). The critical value of signifi1
cance level (p) was taken 0,05.
The research design
Table 1
Predictors of CHF with preserved ejection fraction associated with cardiovascular diseases
Measure
Number of patients  (abs.,  %) or middle level (M±m, Ме )
Patients aged 40359
(n=74)





Male 43 (58,1%) 41 (56,2%) 22 (43,1%)
Female 31 (41,9%) 32 (43,8%) 29 (56,9 %)
Stable angina pectoris
Absent 2 (2,8%) 17 (23,2%) 6 (11,8%)
І!ІІ FC 49 (66,2%) 28 (38,4%) 15 (29,4%)
ІІІ FC 23 (31%) 28 (38,4%) 30 (58,8%)
Arterial hyper!tension
Absent 12 (16,2%) 17 (23,3%) !
II stage 43(58,1%) 39 (53,4%) 34 (66,7%)
III stage 19 (25,7%) 17 (23,3%) 17 (33,3%)
Arterial hyper!tension
1 grade 4 (6,5%) 9 (12,3%) 2 (3,9 %)
2 grade 44 (71%) 39 (53,4%) 20 (39,2 %)
3 grade 14 (22,5%) 25 (34,3%) 29 (56,9 %)
Myocardial infarction in anam!nesis 17 (23%) 23 (31,5%) 12 (23,5%)
CCD (blockades) 11 (14,9%) 5 (6,8%) 11 (21,6%)
Arrhythmia (extrasystole) 11 (14,9%) 15 (20,5%) 7 (13,7%)
Atrial fibrillation 6 (8,1%) 17 (23,2%) 7 (13,7%)
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RESULTS AND DISCUSSION
Various factors play a role in the development of CHF with
preserved ejection fraction and its progression, according to the
literature [5, 16]. Among them we can separate these groups.
The first group of factors associated with the presence of cardiac
disease: coronary heart disease (angina, postinfarction car1
diosclerosis), hypertension, arrhythmias (extrasystoles, atrial
fibrillation) and conduction (blockade). The second group –
extracardiac factors: thyroid disease, chronic obstructive pul1
monary disease (COPD), chronic kidney disease, obesity, dia1
betes, anemia. Cardiovascular diseases and extracardiac factors
associated with CHF with preserved ejection fraction of patients
from different age groups were analyzed.
Patients of all age groups were comparable in anamnesis and
clinical characteristics (p>0,05). Women in the age group over
75 years – 29 (56.9%) prevailed among all other patients with
CHF with preserved ejection fraction that matches with the
data of worldwide studies about prevalence of women in the
structure of CHF with preserved ejection fraction [3, 4, 15, 19].
Angina pectoris II and III functional class (FC) was diag1
nosed among 173 patients (87,3%) of all ages: FC II – among
49 (66,2%), FC III – 23 (31%) among patients up to 59 years
old; among patients from 60 to 75 years: FC II among
28 (38,4%), FC III – 28 (38,4%) and patients older than 76: FC
II among 15 (29,4%) and III FC among 30 (58,8%).
Hypertension was diagnosed among 169 patients (85,4%).
From the first group 43 (58,1%) patients had stage II,
19 (25,7%) – ІІІ stage; in the second group, 39 (53,4%) patients
– II stage, 17 (23,3%) – ІІІ stage; the third group, 34 (66,7%) –
II stage, grade 1, 17 (33,3%) – the ІІІ stage. In ІІІ group all
patients had hypertension (tab. 1).
17 (23%) patients from the first group had a myocardial
infarction in anamnesis (over six months), 23 (31,5%) – in the
second group and 12 (23,5%) – in the third group. Conduction
(block) were in 11 (14,9%) patients from the first group, in
5 (6,8%) – from the second group and in 11 (21,6%) from the
third group. Extrasystole was in 11 (14,9%) patients from the
first group, in 15 (20,5%) from the second group and in
7 (13,7%) from the third group. Atrial fibrillation was detected
in 6 patients (8,1%) from the first group, in 17 (23,2%) from sec1
ond group, in 7 (13,7%) from the third group. Level of indicators
such as myocardial infarction history, extrasystole, atrial fibril1
lation increases with age, but the highest in the age 60–75 years.
Comorbid diseases in patients with chronic heart failure
with preserved ejection fraction, depending on age
We have studied through several factors that may induce
CHF with preserved ejection fraction associated with extracar1
diac pathology: the presence of renal disease, thyroid cancer,
obesity, diabetes, COPD (tab. 2).
During the analyzing the presence of comorbidity in patients
with heart failure with preserved ejection fraction found a high
degree of comorbidity.
It was found that the frequency of registration of COPD
increases with age: in the second age group the frequency of
COPD is 7,5% higher than in the first, in the third – 4,1% high1
er. More than quarter of all patients had diabetes, which is con1
sistent with results from UNIVERS [6]. Thyroid pathology was
the highest in the group from 60 to 75 years. The average level of
BMI in all groups were not significantly different and was
responsible overweight. This found that in all groups registered
a high incidence of obesity – almost half of the patients had obe1
sity: in first group 33 (44,6%) patients, in second – 31 (42,5%)
and 23 (45,1%) patients in third group (tab. 2).
Special analysis requires renal function in patients with CHF.
According to the study, renal pathology (the presence of diabetic or
hypertensive nephropathy, glomerulonephritis or pyelonephritis a
history of kidney cysts) was found almost at third of patients of all
ages. Also we have noticed that GFR was reduced in more patients.
Among them GFR below 60 ml/min/1,73 m2 corresponding
to chronic renal failure was found in 15 (20,2%) patients from
the first group, 27 (37%) patients – from the second group and
29 (56, 9%) from the third group.
Today, the presence of concomitant anemia in patients with
CHF is a factor of negative clinical prognosis that in addition
significantly reduces the quality of life of patients [2]. During
analyzing the average levels of hemoglobin in all age groups
found that the frequency of registration of low hemoglobin level
was the lowest in the group till 59 years (16,3%). 14,9% of them
were patients with medium level of anemia. 
The presence of thyroid disease in patients with CHF
(hypothyroidism, hyperthyroidism) verified under the Order of
the MOH Ukraine № 507 from 28.12.2002 [6]. Established that
the frequency of thyroid diseases registration increases with
patients age. Most thyroid pathology was observed in the group
of 60–75 years. Found that significant number among patients
with CHF with preserved EF was in a hypothyroidism condi1
tion, and the number of patients also increased with age: from
5,4% in patients aged 40 to 59 to 12% in patients aged 75 years.
CONCLUSIONS
1. Increase in the occurrence of hypertension and prevalence of
angina pectoris observed in the presence of CHF and with age
growth. On the other hand, the highest degree of myocardial infarc1
tion and atrial fibrillation was found in the range of 60–75 years.
2. All patients with CHF with preserved ejection fraction
have comorbid pathology. Revealed heterogenity age changes in
the comorbidity: prevalence of functional renal changes, chronic
obstructive pulmonary disease, anemia increases with age.
Moreover in all age groups, almost half of patients had obesity
and a quarter of patients – diabetes mellitus type 2.
Таble 2
Presence of comorbid pathology among patients with CHF with preserved ejection fraction
Measure
Number of patients  (abs.,  %) or middle level (M±m, Ме )
Patients aged 40359
(n=74)




COPD 2 (2,7%) 6 (10,2%) 4 (7,8%)
Renal disease 22 (29,7%) 19 (26%) 15 (29,4%)
Diabetes mellitus 18 (24,3%) 20 (27,4%) 10 (19,6%)
Thyroid gland disease 19 (25,7%) 28 (38,4%) 12 (23,5%)
BMI,kg/m2 M±m (Ме) 29,7±4,6 29,8± 4,0 26,8±3,0
BMI
Normal 23 (31%) 23 (31,5%) 15 (29,4%)
Increased 18 (24,3%) 19 (26%) 13 (25,5%)
Obesity 33 (44,6%) 31 (42,5%) 23 (45,1%)
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Серцево3судинні захворювання 
та коморбідність у пацієнтів з хронічною 
серцевою недостатністю зі збереженою
фракцією викиду залежно від віку
Ю.С. Кушнір, О.В. Курята, Г.О. Доброгорська
Метою дослідження було встановити наявність серцево1судинних
захворювань та коморбідність у пацієнтів з хронічною серцевою
недостатністю зі збереженою фракцією викиду залежно від віку. У
всіх пацієнтів з хронічною серцевою недостатністю зі збереженою
фракцією викиду зустрічається супутня патологія. Виявлено гете1
рогенність вікових змін коморбідної патології: поширеність
функціональних змін нирок, хронічні обструктивні захворювання
нирок, анемії з віком зростає. До того ж, в усіх вікових групах май1
же половина пацієнтів мали ожиріння, а чверть пацієнтів – цукро1
вий діабет 21го типу.
Ключові слова: хронічна сердечна недостатність, збережена
фракція викиду, коморбідность, вік.
Сердечно3сосудистые заболевания 
и коморбидность у пациентов с хронической
сердечной недостаточностью и сохраненной
фракцией выброса в зависимости от возраста
Ю.С. Кушнир, А.В. Курята, Г.А. Доброгорская
Целью исследования было определить наличие сердечно1сосудис1
тых заболеваний и коморбидность у пациентов с хронической сер1
дечной недостаточностью и сохраненной фракцией выброса в за1
висимости от возраста. У всех пациентов с хронической сердечной
недостаточностью с сохраненной фракцией выброса встречается
сопутствующая патология. Выявлена гетерогенность возрастных
изменений коморбидной патологии: распространенность функци1
ональных изменений почек, хронические обструктивные заболе1
вания легких, анемии с возрастом увеличиваются. Более того, во
всех возрастных группах почти половина пациентов имели ожире1
ние, а четверть пациентов – сахарный диабет 21го типа.
Ключевые слова: хроническая сердечная недостаточность, сохра'
ненная фракция выброса, коморбидность, возраст.
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